Please assess the completion status of the following clinical trial:

Trial Title: Human Anti-Tac (Daclizumab) to Treat Juvenile Idiopathic Arthritis (JIA)-Associated Uveitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
* INCLUSION CRITERIA:~  1. Participant is from 6 to 18 years of age, inclusive;~ 2. Participant has a diagnosis of non-infectious uveitis associated juvenile idiopathic arthritis (JIA) requiring treatment to control their intraocular inflammatory disease with anti-inflammatory medications, systemic and/or topical at high frequency intervals (greater than or equal to 3 times a day).~ 3. Participant's uveitis is considered active on current regimen~ 4. Participant has uveitis with at least a grade of 1+ for anterior chamber cells in at least one eye~ 5. Participant's uveitis is currently treated or untreated at the time of enrollment~ 6. Participant has visual acuity in at least one eye of 20/640 or better (Early Treatment Diabetic Retinopathy Study (ETDRS) or Electronic Visual Acuity-Amblyopia Treatment Study (EVA-ATS), log minimum angle of resolution (logMAR) less than 1.54).~ 7. Participant has normal renal or liver function or evidence of no worse than mild abnormalities as defined by the Common Toxicity Criteria for Adverse Events (CTCAE) version 3.0, including:~     Test Parameter Age (yrs) Pediatric Mild Limit~     Serum creatinine 6-12 1.0 mg/dL~     13-18 1.6 mg/dL~     Proteinuria 6-18 3 g/L~     Uric acid 6-18 9.9 mg/dL~     Blood Urea Nitrogen (BUN) 6-18 2.0 upper normal limit~     Aspartate aminotransferase (Serum glutamic-oxaloacetic transaminase) (AST (SGOT)) 6-18 2.5 upper normal limit~     Alanine aminotransferase (Serum glutamic pyruvic transaminase) (ALT (SGPT)) 6-18 2.5 upper normal limit~ 8. Participant agrees not to undergo elective ocular surgery (e.g., cataract extraction) for the first 6 months of the study.~ 9. Participant has an absolute neutrophil count above 750.~ 10. Participant is not currently pregnant or lactating.~ 11. Participant with reproductive potential and who is sexually active agrees to use acceptable birth control methods throughout the course of the study and for 6 months after completion of treatment.~ 12. All participants at enrollment has a parent or legal guardian who is able to understand and sign a consent form on their behalf before entering into the study, and participant signs an assent as a minor.~ 13. Meet American College of Rheumatology Criteria for Juvenile Rheumatoid Arthritis (JRA)/JIA (Appendix) but is not newly diagnosed, and has had systemic treatment for their uveitis.~ 14. Be able to undergo slit lamp biomicroscopy for assessment of anterior chamber cells.~ 15. Be able to comply with the study requirements.~ 16. Be up to date on all recommended childhood immunizations.~EXCLUSION CRITERIA:~1. Participants under the age of 6 years will not be enrolled in the study due to the reported higher incidence of adverse events related or unrelated to the administration of daclizumab in post-transplant pediatric studies compared to children over age 6.~2. Participants who had received previous treatment with an IL-2 directed monoclonal antibody or any other investigational agent that would interfere with the ability to evaluate the safety, efficacy or pharmacokinetics of daclizumab.~3. Participants with a history or diagnosis of Behcet's disease.~4. Participant has a significant active infection.~5. Participant has a history of cancer (other than a non-melanoma skin cancer) diagnosed within the past 5 years.~6. Participant has used latanoprost (Xalatan) within two weeks prior to study enrollment or has a likely need.~7. Participant for whom administration of fluorescein dye is medically contraindicated.~8. Have a media opacity that precludes assessment of anterior chamber inflammation.~9. Be a female who is pregnant or lactating.~10. Refuse to use contraception during the study and 6 months after termination of active study therapy, if child-bearing or fathering potential exists.~11. Have active serious infections or a history of recurring serious infections.~12. Evidence of spondyloarthropathy or enthesopathy.~13. Have active joint or systemic inflammation requiring immediate addition or increase in systemic anti-inflammatory medications.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Daclizumab (Type: EXPERIMENTAL): IV daclizumab

Based on this trial design, predict the completion outcome and termination type (if applicable).